HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

GlaxoSmithKline

ClinicalTrials.gov Identifier:

NCT00349349

First received: July 6, 2006

Last updated: May 9, 2013

Last verified: September 2012

History of Changes

Results First Received: October 20, 2011

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Leukaemia, Lymphocytic, Chronic
Intervention:	Drug: ofatumumab

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
2000 mg Ofatumumab + DR	Ofatumumab intravenous (iv) infusion was initiated at 300 milligrams (mg), followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The independent endpoint review committee (IRC) classified these participants as double refractory (DR), defined as participants who were enrolled in the study and were refractory to both fludarabine and alemtuzumab.
2000 mg Ofatumumab + BFR	Ofatumumab iv infusion was initiated at 300 mg, followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The IRC classified these participants as bulky fludarabine refractory (BFR), defined as participants who were enrolled in the study and were refractory to fludarabine with bulky lymphadenopathy.
2000 mg Ofatumumab + Other	Ofatumumab iv infusion was initiated at 300 mg, followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The IRC classified these participants as "other," defined as participants who were enrolled in the study but did not meet criteria for DR or BFR.

Participant Flow: Overall Study

	2000 mg Ofatumumab + DR	2000 mg Ofatumumab + BFR	2000 mg Ofatumumab + Other
STARTED	95	112	16
COMPLETED	42	50	10
NOT COMPLETED	53	62	6
Adverse Event	5	6	2
Withdrawal by Subject	5	2	1
Withdrawn due to Disease Progression	27	37	1
Death	13	10	1
Other Treatment Selected	2	0	0
Participant Reduced General Condition	0	1	0
Physician Decision	1	2	1
No Response	0	3	0
New Malignancy (Bladder Cancer)	0	1	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
2000 mg Ofatumumab + DR	Ofatumumab iv infusion was initiated at 300 mg, followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The IRC classified these participants as DR, defined as participants who were enrolled in the study and were refractory to both fludarabine and alemtuzumab.
2000 mg Ofatumumab + BFR	Ofatumumab iv infusion was initiated at 300 mg, followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The IRC classified these participants as BFR, defined as participants who were enrolled in the study and were refractory to fludarabine with bulky lymphadenopathy.
2000 mg Ofatumumab + Other	Ofatumumab iv infusion was initiated at 300 mg, followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The IRC classified these participants as "other,"defined as participants who were enrolled in the study but did not meet criteria for DR or BFR.
Total	Total of all reporting groups

Baseline Measures

	2000 mg Ofatumumab + DR	2000 mg Ofatumumab + BFR	2000 mg Ofatumumab + Other	Total
Number of Participants [units: participants]	95	112	16	223
Age [units: Years] Mean ± Standard Deviation	63.2 ± 8.4	64.4 ± 9.3	64.5 ± 7.4	63.9 ± 8.8
Gender [units: Participants]
Female	24	31	5	60
Male	71	81	11	163
Race/Ethnicity, Customized [units: participants]
Asian	1	0	1	2
Black or African American	2	1	0	3
Hispanic or Latino	1	0	0	1
White	88	111	15	214
Arab	1	0	0	1
Yemenite	1	0	0	1
Middle Eastern	1	0	0	1

Outcome Measures

Show All Outcome Measures

1. Primary:

Number of Participants (Par.) Classified as Responders and Non-responders for Objective Response as Assessed by an Independent Endpoint Review Committee (IRC) in Accordance With the National Cancer Institute Working Group (NCIWG) 1996 Guidelines [ Time Frame: Start of treatment (Week 0 of Visit 2) until Week 24 ]

Show Outcome Measure 1

2. Secondary:

Duration of Response [ Time Frame: Start of treatment (Week 0 of Visit 2) until Week 24 ]

Show Outcome Measure 2

3. Secondary:

Progression-Free Survival (PFS) [ Time Frame: Start of treatment (Week 0 of Visit 2) until Week 24 ]

Show Outcome Measure 3

4. Secondary:

Time to Next Chronic Lymphocytic Leukemia (CLL) Treatment [ Time Frame: Time from randomization (Week 0 of Visit 2) until the time of first administration of a CLL treatment other than ofatumumab (assessed for a median of 8.7 weeks currently [or up to 13.3 months]) ]

Show Outcome Measure 4

5. Secondary:

Overall Survival [ Time Frame: Start of randomization (Week 0 of Visit 2) until death (up to a median of 17.1 weeks) ]

Show Outcome Measure 5

6. Secondary:

Percent Change From Baseline to Week 7 in Peripheral CD5+CD19+ Cell Counts [ Time Frame: Baseline (Visit 2) until Week 7 (Visit 9) ]

Show Outcome Measure 6

7. Secondary:

Percent Change From Baseline to Week 7 in Peripheral CD5+CD20+ Cell Counts [ Time Frame: Baseline (Visit 2) until Week 7 (Visit 9) ]

Show Outcome Measure 7

8. Secondary:

Median Percent Change of Tumor Size (Sum of Products Dimensions [SPD]) From Baseline (Visit 2) to Week 24 (Visit 14) [ Time Frame: Baseline (Visit 2) until Week 24 (Visit 14) ]

Show Outcome Measure 8

9. Secondary:

Number of Participants With Complete Resolution of Constitutional Symptoms at Week 24 [ Time Frame: Baseline (Visit 2) and Week 24 ]

Show Outcome Measure 9

10. Secondary:

Number of Participants With Complete Resolution of Lymphadenopathy [ Time Frame: Baseline (Visit 2) to end of study (up to Week 24) ]

Show Outcome Measure 10

11. Secondary:

Number of Participants With Improvement on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale at Week 24 [ Time Frame: Baseline (Visit 2) and Week 24 ]

Show Outcome Measure 11

12. Secondary:

Number of Participants Who Were Positive, Negative, or Had Missing Data for the Indicated Fluorescence in Situ Hybridization (FISH) Prognostic Factors at Screening [ Time Frame: Screening (Visit 1, <=14 days prior to Visit 2) ]

Show Outcome Measure 12

13. Secondary:

Number of Participants With Improvement in Hemoglobin [ Time Frame: Baseline (Visit 2) to Week 28 ]

Show Outcome Measure 13

14. Secondary:

Number of Participants With Improvement in Thrombocytopenia (Thromb.) [ Time Frame: Baseline (Visit 2) to Week 28 ]

Show Outcome Measure 14

15. Secondary:

Number of Participants With Improvement in Neutropenia [ Time Frame: Baseline (Visit 2) to Week 28 ]

Show Outcome Measure 15

16. Secondary:

Number of Participants With Complete Resolution of Hepatomegaly [ Time Frame: Baseline (Visit 2) until Week 24 ]

Hide Outcome Measure 16

Measure Type	Secondary
Measure Title	Number of Participants With Complete Resolution of Hepatomegaly
Measure Description	Participants with complete resolution of enlarged liver (hepatomegaly) were defined as those with an enlarged palpable liver at baseline followed by the absence of hepatomegaly post- baseline (i.e., the liver was of normal size). Liver size was assessed by physical examination and documented as “centimeters” under the costal margin with relative changes in spleen size in 1 dimension calculated based on palpated numeric measurements (as per the 1996 NCIWG guidelines).
Time Frame	Baseline (Visit 2) until Week 24
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
FAS. Data were provided for the number of participants with hepatomegaly from baseline attending each visit. Participants withdrawn during the study were not analyzed. Only participants with baseline hepatomegaly and a post-baseline assessment are included.

Reporting Groups

	Description
2000 mg Ofatumumab + DR	Ofatumumab iv infusion was initiated at 300 mg, followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The IRC classified these participants as DR, defined as participants who were enrolled in the study and were refractory to both fludarabine and alemtuzumab.
2000 mg Ofatumumab + BFR	Ofatumumab iv infusion was initiated at 300 mg, followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The IRC classified these participants as BFR, defined as participants who were enrolled in the study and were refractory to fludarabine with bulky lymphadenopathy.
2000 mg Ofatumumab + Other	Ofatumumab iv infusion was initiated at 300 mg, followed by seven weekly 2000 mg infusions and then four monthly infusions of 2000 mg for a duration of 24 weeks. The IRC classified these participants as "other,"defined as participants who were enrolled in the study but did not meet criteria for DR or BFR.

Measured Values

	2000 mg Ofatumumab + DR	2000 mg Ofatumumab + BFR	2000 mg Ofatumumab + Other
Number of Participants Analyzed [units: participants]	21	28	7
Number of Participants With Complete Resolution of Hepatomegaly [units: participants]	17	19	4

No statistical analysis provided for Number of Participants With Complete Resolution of Hepatomegaly

17. Secondary:

Number of Participants Who Experienced Any Adverse Event [ Time Frame: From first infusion (Visit 2/Week 0) to Visit 21 (Month 24 of follow-up [up to Month 48]) or time of withdrawal (treatment and follow-up) ]

Show Outcome Measure 17

18. Secondary:

Number of Participants With Complete Resolution of Splenomegaly [ Time Frame: Baseline (Visit 2) until Week 24 ]

Show Outcome Measure 18

19. Secondary:

Cmax and Ctrough at Dose 1 (Visit 2, Week 0), Dose 8 (Visit 9, Week 7), and Dose 12 (Visit 14, Week 24) [ Time Frame: Visit 2 (Week 0), Visit 9 (Week 7), and Visit 14 (Week 24) ]

Show Outcome Measure 19

20. Secondary:

AUC (0-inf) and AUC(0-tau) at Dose 8 (Visit 9, Week 7) and Dose 12 (Visit 14, Week 24) [ Time Frame: Visit 9 (Week 7) and Visit 14 (Week 24) ]

Show Outcome Measure 20

21. Secondary:

Half-life (t1/2) at Dose 8 (Visit 9, Week 7) and at Dose 12 (Visit 14, Week 24) [ Time Frame: Visit 9 (Week 7) and Visit14 (Week 24) ]

Show Outcome Measure 21

22. Secondary:

Clearance (CL) After Dose 8 (Visit 9, Week 7) and Dose 12 (Visit 14, Week 24) [ Time Frame: Visit 9 (Week 7) and Visit 14 (Week 24) ]

Show Outcome Measure 22

23. Secondary:

Volume of Distribution at Steady State (Vss) at Dose 8 (Visit 9, Week 7) and at Dose 12 (Visit 14, Week 24) [ Time Frame: Visit 9 (Week 7) and Visit 14 (Week 24) ]

Show Outcome Measure 23

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343

No publications provided by GlaxoSmithKline

Publications automatically indexed to this study:

Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A; Hx-CD20-406 Study Investigators. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011 Nov 10;118(19):5126-9. Epub 2011 Aug 19.

Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1749-55. Epub 2010 Mar 1.

Responsible Party:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00349349 History of Changes
Other Study ID Numbers:	111773, Hx-CD20-406
Study First Received:	July 6, 2006
Results First Received:	October 20, 2011
Last Updated:	May 9, 2013
Health Authority:	United States: Food and Drug Administration

To Top